▲ Peaking
Business
Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive
Tempus AI is acquiring cancer-monitoring firm Personalis for $1.5 billion, though the news triggered a decline in share prices for both companies.
Acquire Personalis More Tightly Integrating Molecular Residual Disease MRD
1 news trends Newsylist has tracked involving Acquire Personalis More Tightly Integrating Molecular Residual Disease MRD — newest first.